Crossmark

SARS-CoV2 RT-PCR assays: In vitro comparison of 4 WHO approved protocols on clinical specimens and its implications for real laboratory practice through variant emergence

Crossref DOI link: https://doi.org/10.1186/s12985-022-01784-4

Published Online: 2022-03-28

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gdoura, Mariem https://orcid.org/0000-0002-2031-6534
Abouda, Imen

Mrad, Mehdi

Ben Dhifallah, Imen

Belaiba, Zeineb

Fares, Wasfi

Chouikha, Anissa

Khedhiri, Maroua

Layouni, Kaouther

Touzi, Henda

Sadraoui, Amel

Hammemi, Walid

Meddeb, Zina

Hogga, Nahed

Ben Fadhel, Sihem

Haddad-Boubaker, Sondes

Triki, Henda
Funding

Funding for this research was provided by:

Ministère de l’Enseignement Supérieur et de la Recherche Scientifique
License Information

Text and Data Mining valid from 2022-03-28

Version of Record valid from 2022-03-28
More Information

Article History

Received: 9 January 2022

Accepted: 14 March 2022

First Online: 28 March 2022

Declarations

:

: The samples were collected as part of diagnosis activity. The use of these samples was approved by the Institutional Review Board of Pasteur Institute of Tunis under ID number: 2020/27/I/LR16IPT. According to the approval and as samples were fully anonymized, the Bioethics committee waived the requirement for informed consent.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below